<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Altered expression of Bcl-2 family proteins plays central roles in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> dysregulation in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:hpo ids='HP_0001909'>leukemia</z:hpo>, promoting malignant cell expansion and contributing to chemoresistance </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we compared the toxicity and efficacy in mice of natural product gossypol and its semisynthetic derivative apo-gossypol, compounds that bind and inhibit antiapoptotic Bcl-2 family proteins </plain></SENT>
<SENT sid="2" pm="."><plain>Daily oral dosing studies showed that mice tolerate doses of apogossypol 2- to 4-times higher than gossypol </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0235378,C0348754" disease_type="Disease or Syndrome;Injury or Poisoning" abbrv="">Hepatotoxicity</z:e> and gastrointestinal toxicity represented the major adverse activities of gossypol, with apogossypol far less toxic </plain></SENT>
<SENT sid="4" pm="."><plain>Efficacy was tested in transgenic mice in which Bcl-2 is overexpressed in B cells, resembling low-grade follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in humans </plain></SENT>
<SENT sid="5" pm="."><plain>In vitro, Bcl-2-expressing B cells from transgenic mice were more sensitive to cytotoxicity induced by apogossypol than gossypol, with LD50 values of 3 to 5 microM and 7.5 to 10 microM, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo, using the maximum tolerated dose of gossypol for sequential daily dosing, apogossypol displayed superior activity to gossypol in terms of reducing <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> and reducing B-cell counts in spleens of Bcl-2-transgenic mice </plain></SENT>
<SENT sid="7" pm="."><plain>Taken together, these studies indicate that apogossypol is superior to parent compound gossypol with respect to toxicology and efficacy, suggesting that further development of this compound for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy is warranted </plain></SENT>
</text></document>